PUBLIC COMPANY
save$IVVDInvivyd, Inc.
$IVVDNew Haven, CT, USupdated 21d ago
community read0 votes
pipeline
2
marketed
1
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 31Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Study of VYD2311 for the Prevention of COVID-19
- phase3A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2
- phase1A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants
- phase3Evaluation of ADG20 for the Prevention of COVID-19
- —Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments
- phase1A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants
- phase3Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that